Cholestyramine for Oral Suspension NDC 62135-008

NDC codes

FDA NDC Directory

Product NDC (as listed)62135-008Labeler and product segments. Claims need a package NDC.

Product NDC at billing width62135-0008Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
62135-008-56	62135000856	378 g in 1 CAN (62135-008-56)Marketed from Jan 3, 2023

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Cholestyramine for Oral Suspension
Generic name (nonproprietary): cholestyramine for oral suspension
Active ingredients: Cholestyramine — 4 g/9g
Dosage form: Powder
Route: Oral
Labeler: Chartwell RX, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 074561
Marketing start: Aug 15, 1996
Listing expires: Dec 31, 2026
Other FDA classes: Bile-acid Binding Activity (Mechanism)
Identifiers: Product ID 62135-008_f1d8692b-deb3-d55f-e053-2a95a90ae615SPL ID f1d8692b-deb3-d55f-e053-2a95a90ae615SPL set ID 80db0042-0c05-4509-8a6b-fa9f4783629aRxCUI 848943, 1801279UNII 4B33BGI082UPC 0362135008567, 0362135937546
Pharmacologic class: Bile Acid Sequestrant

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N462135000856 followed by a unit qualifier and the quantity

Package 62135-0008-56. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 9, 2023.

Indications (excerpt from the label)

INDICATIONS AND USAGE 1) Cholestyramine is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and co…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)